Axitinib Licensed by Pfizer

Catalog No.S1005

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Axitinib Chemical Structure

Axitinib Chemical Structure
Molecular Weight: 386.47

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Axitinib Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Targets VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)

 View  More

IC50 0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM
In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellM{P5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXoVXJKSzVyPUCuNFAxODVzMzFOwG0>NYD3RmN2W0GQR1XS
NCI-H1703NID4cY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\TVHVKSzVyPUCuNFAxQTB{IN88US=>NV7DW4dxW0GQR1XS
KASUMI-1NIPkb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmm3TWM2OD1yLkCwOlgzKM7:TR?=MVzTRW5ITVJ?
CGTH-W-1NEHaemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\ITGlEPTB;MD6wNFczOiEQvF2=MkHiV2FPT0WU
A204NH3WU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnHTWM2OD1yLkCwPVkzKM7:TR?=MmTlV2FPT0WU
HOP-62MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XQe2lEPTB;MD6xNFg{PiEQvF2=M3[0WXNCVkeHUh?=
H-EMC-SSMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HsfGlEPTB;MD6xNVAxPSEQvF2=M2nNfHNCVkeHUh?=
KU812NEPVWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwMU[1O|ch|ryPMXXTRW5ITVJ?
EM-2NGTMR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfHOZlKSzVyPUCuNVY5OTZizszNMnT3V2FPT0WU
LAMA-84M3G4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTBwMUe2OlUh|ryPMYPTRW5ITVJ?
JARNGTTbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TBOmlEPTB;MD6yN|k5QSEQvF2=NUDodY9XW0GQR1XS
G-361NGPPSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rVWmlEPTB;MD6zNlMzPSEQvF2=NHTVeYxUSU6JRWK=
KG-1NG\kSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XDWGlEPTB;MD6zO|Y1OiEQvF2=MVfTRW5ITVJ?
BV-173Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfaSVVKSzVyPUCuN|k{OiEQvF2=NHvIdo9USU6JRWK=
K5NXfJb|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PHbmlEPTB;MD60NlEzPyEQvF2=MVXTRW5ITVJ?
MEG-01MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfPWlF{UUN3ME2wMlQzOzZzIN88US=>M2nVZXNCVkeHUh?=
MFM-223NH7hWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmj4TWM2OD1yLkS0O|c3KM7:TR?=M1zNXXNCVkeHUh?=
BE-13NHzsWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3qTWM2OD1yLkWxNFA5KM7:TR?=MYLTRW5ITVJ?
NEC8NVjiWo1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LVcmlEPTB;MD63NlEyOyEQvF2=NXzCXpc3W0GQR1XS
SW756M2LXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTBwOUm4OFYh|ryPMmXpV2FPT0WU
A2780NGDEbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjkT3JEUUN3ME2xMlAyOTR4IN88US=>MkG3V2FPT0WU
NB14M{TGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfFeJBKSzVyPUGuNFE5ODFizszNNGTSXJJUSU6JRWK=
H4MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NESzb2JKSzVyPUGuNFY1OjJizszNNUPTeVZFW0GQR1XS
SK-OV-3NXW2cGxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3ThOmlEPTB;MT6wOlY{OyEQvF2=MUDTRW5ITVJ?
AN3-CANVfwUpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjUTWM2OD1zLkC4N|g6KM7:TR?=NWr2bJJIW0GQR1XS
A427NWG1OotGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLZWmZQUUN3ME2xMlExOzhzIN88US=>M{Huc3NCVkeHUh?=
ES7MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGX5e4tKSzVyPUGuNVE{OzRizszNMUnTRW5ITVJ?
AGSNEX3UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;IRZQzUUN3ME2xMlEyOzl3IN88US=>NUnRblV2W0GQR1XS
G-402NUTWN5pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml21TWM2OD1zLkG0Olk1KM7:TR?=Mli5V2FPT0WU
ES5M{DaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIO4dnhKSzVyPUGuNVczPDhizszNMoHUV2FPT0WU
DELM{PBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTFwMkW0OVch|ryPMofkV2FPT0WU
NB10MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHlb5VKSzVyPUGuN|I2PTdizszNNXPy[Y5PW0GQR1XS
NCI-H1581MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\HNmlEPTB;MT6zPVA1OiEQvF2=Ml\RV2FPT0WU
D-566MGMkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTFwNEC2PFMh|ryPNFjpSYxUSU6JRWK=
LXF-289MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4[zfmlEPTB;MT60N|k6PiEQvF2=NX3m[ol4W0GQR1XS
BT-549NWjwTJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmSwTWM2OD1zLkW2PVA6KM7:TR?=M4\UXHNCVkeHUh?=
NKM-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkK4TWM2OD1zLk[wOVU3KM7:TR?=NVvQblloW0GQR1XS
SW780M4DpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnpcYZKSzVyPUGuOlUyPThizszNMX3TRW5ITVJ?
NCI-H292M{fQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LGWGlEPTB;MT62OlM5OyEQvF2=MWDTRW5ITVJ?
HMV-IINVjPZYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfUUJRKSzVyPUGuO|A1QDhizszNMkHlV2FPT0WU
ALL-POMlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXL5UW45UUN3ME2xMlgxODF3IN88US=>Mo\xV2FPT0WU
UACC-257M{j3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTFwOEKxOlMh|ryPM1vW[nNCVkeHUh?=
PA-1NX\XcHVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLHXYdGUUN3ME2xMlgzPzJ3IN88US=>MUTTRW5ITVJ?
HD-MY-ZMoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDsTWM2OD1zLki2NlgyKM7:TR?=NVzwUpRXW0GQR1XS
HSC-4NW\sWnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHRNIlDUUN3ME2xMlk{QDN7IN88US=>M4TXc3NCVkeHUh?=
GCTNIXp[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLYdohKSzVyPUKuNFA6OTZizszNNIPwSlhUSU6JRWK=
RT-112MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHRfodKSzVyPUKuNVM1OjRizszNNFXPVo5USU6JRWK=
A172NF3BcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rUT2lEPTB;Mj6xN|YxPiEQvF2=MVvTRW5ITVJ?
HCE-TMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJwMkC1PVgh|ryPMl25V2FPT0WU
YH-13Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJwMkG2O|Eh|ryPNWL6Rm0yW0GQR1XS
DK-MGM1rn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTJwMkO4N|Qh|ryPM3;O[3NCVkeHUh?=
ACNMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\zcGgyUUN3ME2yMlI{QDd3IN88US=>NHzrNXBUSU6JRWK=
VA-ES-BJNGriOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DZT2lEPTB;Mj6yOFk2PyEQvF2=NHfkO5FUSU6JRWK=
L-363MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTJwMkiwOlEh|ryPMWnTRW5ITVJ?
HuH-7NWmxOYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzJbpZKSzVyPUKuOFIyPjVizszNNH7v[5ZUSU6JRWK=
A4-FukMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTJwNEexOlgh|ryPNVrYe5ZIW0GQR1XS
T-24NFPpdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLTUHBuUUN3ME2yMlQ5ODN5IN88US=>NH7Re5RUSU6JRWK=
GOTONIXhXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTJwNUOwNVMh|ryPMVvTRW5ITVJ?
MV-4-11MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTJwNUmxOlkh|ryPMmrYV2FPT0WU
DMS-114NGPqeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4mzVGlEPTB;Mj62OlM1PSEQvF2=M2rzN3NCVkeHUh?=
MHH-NB-11MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXWTWM2OD1{LkewNlk6KM7:TR?=NVrzeYFiW0GQR1XS
CHP-212M2HwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPRTWM2OD1{LkiyNFkyKM7:TR?=NWjx[WFCW0GQR1XS
DMS-273M{DMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjVOJFKSzVyPUKuPVAzODdizszNMXXTRW5ITVJ?
SF295MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7tTWM2OD1|LkCyOVk4KM7:TR?=MnvlV2FPT0WU
NCI-H1563NU\ZbXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTNwMUWwNFUh|ryPMkC2V2FPT0WU
NCI-H446MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTsTWM2OD1|LkKyPFA2KM7:TR?=NF:yZW9USU6JRWK=
HCC1806Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLQXHJnUUN3ME2zMlI4PjV5IN88US=>M{LKV3NCVkeHUh?=
SF126M{\MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTNwM{CwNVch|ryPNHLac|NUSU6JRWK=
SW982NU\E[YtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2D3VWlEPTB;Mz6zN|g4PSEQvF2=M4L2fXNCVkeHUh?=
ES8MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[0TWM2OD1|LkO0PVk6KM7:TR?=NELYeYZUSU6JRWK=
SCC-4Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTNwNUCzPVYh|ryPNILiNpdUSU6JRWK=
RPMI-8226NGPYbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHaVYZKSzVyPUOuOlI3OTZizszNM3;B[nNCVkeHUh?=
EW-11MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zoeGlEPTB;Mz62N|AzOiEQvF2=MmTlV2FPT0WU
COR-L105MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTNwNkOzN|Qh|ryPMoiyV2FPT0WU
ES1NH7XcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTWTWM2OD1|LkizNFk1KM7:TR?=MYrTRW5ITVJ?
KMOE-2MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDwWFRKSzVyPUOuPVE5ODhizszNNWjpVlVbW0GQR1XS
ABC-1M4f5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnruTWM2OD1|LkmzPVEyKM7:TR?=NXS4[2xuW0GQR1XS
NCI-H526NXrvPGVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3ZOphKSzVyPUOuPVkyOjZizszNMUPTRW5ITVJ?
HCC1395MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmH2TWM2OD1|Lkm5OFg1KM7:TR?=NHXq[2RUSU6JRWK=
DU-145MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDnW3JlUUN3ME20MlEzQDJ3IN88US=>M176[XNCVkeHUh?=
JEG-3M3vGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1u5XGlEPTB;ND6xOVkyPiEQvF2=NWLzb4RUW0GQR1XS
HCC1187NVOxb2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTRwMkG1PVch|ryPM4TYZnNCVkeHUh?=
LC-2-adNWXWO41VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXYdHlOUUN3ME20MlIzOTd5IN88US=>NHHieZJUSU6JRWK=
ONS-76MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfjTWM2OD12LkK0NVkzKM7:TR?=NUe4bFg3W0GQR1XS
CAL-27NIe3XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYe1VHR2UUN3ME20MlI1OzR2IN88US=>Mlj1V2FPT0WU
8-MG-BANW\WWG5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[0TWM2OD12LkK2OlU5KM7:TR?=M3XDcnNCVkeHUh?=
HGC-27NGTueYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzlTWM2OD12LkK5OlYh|ryPMk\LV2FPT0WU
Hs-578-TNETvbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3icIpHUUN3ME20MlMyPDZ6IN88US=>NGHsZY9USU6JRWK=
EW-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvhTWM2OD12LkWzNFE1KM7:TR?=NVjMOHNVW0GQR1XS
SW1573NUTl[Xd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{iwb2lEPTB;ND61OVE3OyEQvF2=MULTRW5ITVJ?
SNU-423M376eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoT5TWM2OD12Lk[wO|kh|ryPMnPlV2FPT0WU
HOSM{P3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTRwNkm3O{DPxE1?M13i[3NCVkeHUh?=
LB1047-RCCNV3kOnByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTRwOEG0NVgh|ryPM2Lq[nNCVkeHUh?=
ChaGo-K-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTRwOEmwOFgh|ryPMofyV2FPT0WU
A3-KAWMoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTsPFhKSzVyPUSuPVc{PTJizszNMnnrV2FPT0WU
CAS-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLqTWM2OD12Lkm5PVA5KM7:TR?=NWrZeo5pW0GQR1XS
NBsusSRNX\BeG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlW1TWM2OD13LkCzOVE1KM7:TR?=NUe5R3FOW0GQR1XS
KM12MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v6WWlEPTB;NT6yPVgzPyEQvF2=M3W0N3NCVkeHUh?=
NCI-H1155M13kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fle2lEPTB;NT6zPFE5PSEQvF2=MoDwV2FPT0WU
EFM-19M2Xpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDpO3JKSzVyPUWuOFE4OzdizszNNH7TVI1USU6JRWK=
D-392MGNWLzV21WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTVwNUe4OFkh|ryPNVjpVZpKW0GQR1XS
JVM-3NV7jO2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHJelRKSzVyPUWuO|I{OjVizszNMoHPV2FPT0WU
EW-16MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\CTWM2OD13Lke1OVg{KM7:TR?=MmTwV2FPT0WU
KARPAS-45M1rHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;iRmJHUUN3ME21Mlg1OzJ3IN88US=>NH\L[|ZUSU6JRWK=
NCI-H28MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTVwOEe5NVgh|ryPMmqxV2FPT0WU
COLO-829M4fkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTVwOUG1NFQh|ryPNHrrS45USU6JRWK=
KM-H2NHzVdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWO1RZhTUUN3ME21MlkzOzl3IN88US=>M1u0e3NCVkeHUh?=
NCI-H82MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXSTWM2OD13LkmyO|cyKM7:TR?=MXvTRW5ITVJ?
OAW-42MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7TOolKSzVyPUWuPVg5OjFizszNNUiye4xuW0GQR1XS
A704MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLTcnlKSzVyPU[uNVA2PzRizszNMWfTRW5ITVJ?
NCI-H1048NGPDVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTZwMUC1PVkh|ryPNUHXU4xrW0GQR1XS
LOXIMVINUHP[JJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XsSGlEPTB;Nj6xNVI1QCEQvF2=MX;TRW5ITVJ?
MKN45M4fSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XuXmlEPTB;Nj6yOlAyPiEQvF2=MWrTRW5ITVJ?
D-502MGMlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHVTWM2OD14LkK4PFU4KM7:TR?=NHLEdlFUSU6JRWK=
HUTU-80NWLCOGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4j0b2lEPTB;Nj60NVY5QCEQvF2=NVXlN21[W0GQR1XS
S-117NHfTVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojkTWM2OD14LkWwNlY4KM7:TR?=Ml:1V2FPT0WU
HCC1569MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTZwNUO3N|ch|ryPNVLJc4hYW0GQR1XS
J-RT3-T3-5NUPEZXp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3G1[GlEPTB;Nj61OFU4OiEQvF2=MVfTRW5ITVJ?
OC-314MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfWTWM2OD14LkmxNVU6KM7:TR?=MWXTRW5ITVJ?
SNU-449MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUi0U5llUUN3ME23MlAyODd{IN88US=>MWfTRW5ITVJ?
NCI-H720NF25O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTdwMUmzOFUh|ryPNIm2U3JUSU6JRWK=
KP-N-YSM2G0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETLWIVKSzVyPUeuNlA4OiEQvF2=NE\4RYVUSU6JRWK=
IGROV-1NVnDcINMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;hTWM2OD15LkOyN|g3KM7:TR?=MXrTRW5ITVJ?
SK-PN-DWNXjjb|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTrTWM2OD15LkS4NVUh|ryPNHW2R2dUSU6JRWK=
HCC1419NHq5cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljDTWM2OD15LkWzJO69VQ>?NH7hSpdUSU6JRWK=
HAL-01MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInzWnVKSzVyPUeuOlA3PDRizszNNGnqSGtUSU6JRWK=
HCC2998MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33mVWlEPTB;Nz62NFc1OyEQvF2=NEHDXodUSU6JRWK=
SK-N-FIMk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTnTWM2OD15Lk[zNFM{KM7:TR?=MoP6V2FPT0WU
GI-ME-NMmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPaTWM2OD15Lk[0PVM1KM7:TR?=NH3WTnhUSU6JRWK=
SW1088MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELSfXlKSzVyPUeuOlU5OjZizszNNV:1WIw2W0GQR1XS
IA-LMNHzSN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PrTGlEPTB;Nz62PFYyOyEQvF2=NYrwO21EW0GQR1XS
SK-NEP-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTdwNkm2NUDPxE1?NH:zZXJUSU6JRWK=
MDA-MB-415MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXf4SJZTUUN3ME23Mlg6OTh4IN88US=>NF;JUIxUSU6JRWK=
COLO-800M1\0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzNeItKSzVyPUeuPVQ1QTJizszNMnH2V2FPT0WU
NCI-H2228NHO0WZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jHOmlEPTB;OD6xOVc5OyEQvF2=NF\5[4RUSU6JRWK=
D-423MGMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRThwMkG3NkDPxE1?MYHTRW5ITVJ?
TE-1M1;2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjLdIpKSzVyPUiuOFQ{OTZizszNMXfTRW5ITVJ?
NOS-1M2XOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7ITWM2OD16LkWxOVM1KM7:TR?=MWXTRW5ITVJ?
8505CMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVmwUXpzUUN3ME24MlY1QDJ2IN88US=>M4nDZXNCVkeHUh?=
HEC-1NITpeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXXTWM2OD16Lke4OFM6KM7:TR?=MUXTRW5ITVJ?
TE-11NG\i[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2joSWlEPTB;OD65PVU2OSEQvF2=MmrqV2FPT0WU
CTB-1NF\oZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HwdWlEPTB;OT6wNVQ{OyEQvF2=NX\XeGp2W0GQR1XS
TGBC11TKBNGHMNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\oeFBKSzVyPUmuNFIzPDFizszNNGHmUIxUSU6JRWK=
NB17M{TCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTlwMUi4O{DPxE1?MlK3V2FPT0WU
BeckerMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fUT2lEPTB;OT60NVk1PCEQvF2=Mn3qV2FPT0WU
SN12CMmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfDTWM2OD17LkS1NlM1KM7:TR?=NXTyV3BxW0GQR1XS
COLO-320-HSRMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHsTWM2OD17Lk[wNlM4KM7:TR?=MUPTRW5ITVJ?
D-283MEDNY\ZbYlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTlwNkOwO|Ih|ryPMX\TRW5ITVJ?
D-263MGM3;ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3oWGZNUUN3ME25Mlg{Ozh2IN88US=>MnvuV2FPT0WU
MEL-JUSOM4LPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlL5TWM2OD17LkmwNVI4KM7:TR?=MX;TRW5ITVJ?
T98GM2DTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIn3TldKSzVyPUmuPVAzODNizszNMXfTRW5ITVJ?
HLEMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTlwOUC5NFkh|ryPMYrTRW5ITVJ?
Ca9-22MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjE[|hKSzVyPUGwMlA3PjVizszNMXHTRW5ITVJ?
OS-RC-2NXLuTmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnBc5dKSzVyPUGwMlExPDVizszNMnvWV2FPT0WU
T47DMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHX6NndKSzVyPUGwMlE2PSEQvF2=M3X2XXNCVkeHUh?=
GI-1M{m5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDHe5NHUUN3ME2xNE4{PTN|IN88US=>M4HBZ3NCVkeHUh?=
NUGC-3NGrySXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDtcpltUUN3ME2xNE41PDB{IN88US=>M4HTOnNCVkeHUh?=
MDA-MB-361MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFyLkS0N|Ih|ryPNHq1XIFUSU6JRWK=
SCC-15NGLWOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTFyLkS3NVgh|ryPNFrr[IdUSU6JRWK=
KS-1M4P1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7wUWFCUUN3ME2xNE43OzBzIN88US=>M3X6NXNCVkeHUh?=
CAL-12TMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFyLk[zOlEh|ryPNUTsWVVOW0GQR1XS
OVCAR-4Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFyLkewOlgh|ryPMlrOV2FPT0WU
HuP-T4M2ezZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPwXnZKSzVyPUGxMlA{OjhizszNM1j4N3NCVkeHUh?=
NCI-H358NXT1Z45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzVWY15UUN3ME2xNU4zPjV5IN88US=>MUPTRW5ITVJ?
HO-1-N-1NGHhbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHIXJR3UUN3ME2xNU4{Ozl6IN88US=>M1zWVHNCVkeHUh?=
NH-12MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHq3VIVKSzVyPUGxMlU{PzhizszNMXzTRW5ITVJ?
MOLT-4NGXMUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXrTWM2OD1zMT61PVg2KM7:TR?=M2TUW3NCVkeHUh?=
K-562MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nQV2lEPTB;MUGuO|I1QCEQvF2=M{fMWXNCVkeHUh?=
ES6M{PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTFzLki1PFEh|ryPMYjTRW5ITVJ?
RO82-W-1M1P5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTFzLkmwOlQh|ryPNWTjU5p3W0GQR1XS
Ramos-2G6-4C10MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTFzLkmzNkDPxE1?MXXTRW5ITVJ?
23132-87NF3hNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfNSnJKSzVyPUGyMlA5OjFizszNNGTqdIhUSU6JRWK=
A549NVvaZVJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1j6cGlEPTB;MUKuN|I5PSEQvF2=M4rBTHNCVkeHUh?=
NCI-H23NX7BPGttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTnXIFCUUN3ME2xNk42ODJ4IN88US=>MXrTRW5ITVJ?
H9MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nZR2lEPTB;MUKuOVU4PyEQvF2=MkewV2FPT0WU
LB771-HNCMnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXmU29EUUN3ME2xNk44PjVizszNMnvwV2FPT0WU
QIMR-WILMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLYTWM2OD1zMj64NlU5KM7:TR?=MXjTRW5ITVJ?
HSC-3MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF{LkmyO|Yh|ryPNXzwVphUW0GQR1XS
PFSK-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DyNWlEPTB;MUKuPVUxPyEQvF2=MnT3V2FPT0WU
ETK-1MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zIOWlEPTB;MUOuNFc4QSEQvF2=M1HaeHNCVkeHUh?=
SW1710M1vlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DWe2lEPTB;MUOuN|Y1OSEQvF2=MoToV2FPT0WU
COLO-684NIPyUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[zWHFTUUN3ME2xN{41PTRzIN88US=>M1npPXNCVkeHUh?=
RPMI-7951MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\hTGlEPTB;MUOuOVE{PiEQvF2=NYLmUotXW0GQR1XS
A101DNITRW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzvTWM2OD1zMz61N|Q6KM7:TR?=NEP5RmpUSU6JRWK=
KE-37M1voPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS2TWM2OD1zMz61PFg4KM7:TR?=NFnXVphUSU6JRWK=
SiHaNFjscWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\6W21KSzVyPUGzMlg{PDZizszNM373TnNCVkeHUh?=
NCI-H226NIXBWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTYTnZKSzVyPUGzMlg5ODhizszNM{fjOnNCVkeHUh?=
DBNEHnTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPYdHk{UUN3ME2xN{46QTJ6IN88US=>NGDvcGRUSU6JRWK=
HT-1197MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1roSGlEPTB;MUSuNFgxQSEQvF2=MVzTRW5ITVJ?
SBC-5NF\UflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHCTWM2OD1zND6xN|YzKM7:TR?=MmjKV2FPT0WU
VMRC-RCZM4HvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\MTWM2OD1zND61O|c1KM7:TR?=M1[5dXNCVkeHUh?=
697NW\5SIhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjaXVNbUUN3ME2xOE43OjdizszNNInV[lRUSU6JRWK=
OMC-1M3XP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXrTWM2OD1zND63PFg5KM7:TR?=NYriVJcxW0GQR1XS
SKG-IIIaMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILiXWtKSzVyPUG0MlgxODFizszNM2f1PXNCVkeHUh?=
DOKM320Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NET0eJdKSzVyPUG0Mlk6OzNizszNNELhd|lUSU6JRWK=
NCI-H2029MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDRWVdKSzVyPUG1MlM3ODJizszNMmrXV2FPT0WU
NCI-H2009MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrwd|BKSzVyPUG1MlUxQTVizszNMVjTRW5ITVJ?
LK-2NXHQZZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjqS|FKSzVyPUG1MlY1PDlizszNNEPz[W1USU6JRWK=
NCI-H661Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Xjc2lEPTB;MUWuPVA4PSEQvF2=NHfWe5lUSU6JRWK=
GT3TKBMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnmUGlKSzVyPUG2MlA3PzZizszNM4Lie3NCVkeHUh?=
GP5dNIe1elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfETWM2OD1zNj6zOFIh|ryPNGfPRYZUSU6JRWK=
SK-MEL-2MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjlUVdKSzVyPUG2MlQ1QDVizszNNIPMepBUSU6JRWK=
SK-UT-1MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\MTWM2OD1zNj61OlUh|ryPMoS3V2FPT0WU
NB7Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTF4Lk[5O|Eh|ryPM3vIN3NCVkeHUh?=
NCI-H460NGTuWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HYWWlEPTB;MU[uO|MzPiEQvF2=NUD2co9sW0GQR1XS
8305CNUjVRWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37XUWlEPTB;MU[uO|g4PyEQvF2=Mkj4V2FPT0WU
CaR-1MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGra[2ZKSzVyPUG2MlgyOTFizszNMYrTRW5ITVJ?
D-247MGNGDLbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jPPGlEPTB;MU[uPFYzPSEQvF2=NXnpVoNXW0GQR1XS
LoVoNIrse2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTF4Lkm0PFgh|ryPM2PBR3NCVkeHUh?=
NCI-H2405MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF5LkG5NFgh|ryPMVTTRW5ITVJ?
AU565NY\a[5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHpUYpEUUN3ME2xO{4zOjVizszNMmfHV2FPT0WU
OCI-AML2MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fXT2lEPTB;MUeuOVMyPyEQvF2=Ml;hV2FPT0WU
22RV1NHPmNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rEPWlEPTB;MUeuOVg5PCEQvF2=MV\TRW5ITVJ?
HT-144MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\pbWlEPTB;MUeuOlU6QCEQvF2=MWPTRW5ITVJ?
HuO9M2H3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTF5LkewN|Eh|ryPMoT3V2FPT0WU
DaoyMmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHhSHhVUUN3ME2xO{44OTh2IN88US=>NW\TOGtvW0GQR1XS
SJRH30MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jXSGlEPTB;MUeuPFQ5QSEQvF2=NIDaV2JUSU6JRWK=
CHL-1NV3ab4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHIUW1XUUN3ME2xO{46OjR7IN88US=>NUDFdGpOW0GQR1XS
J82NYnx[VJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\YTWM2OD1zNz65OlM2KM7:TR?=MV3TRW5ITVJ?
COR-L23MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XVcWlEPTB;MUiuNFAyOSEQvF2=MnPQV2FPT0WU
SNU-C2BMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2S4emlEPTB;MUiuNlI4PiEQvF2=MlTVV2FPT0WU
NCI-H1770MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3riWWlEPTB;MUiuOFYyPSEQvF2=M1jDbnNCVkeHUh?=
MHH-PREB-1M13vUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkCxTWM2OD1zOD61Olk4KM7:TR?=NITOPHdUSU6JRWK=
ES3NWrLNlY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTF6LkW4PFMh|ryPMXLTRW5ITVJ?
MDA-MB-231MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmj2TWM2OD1zOD62OVAzKM7:TR?=MoG4V2FPT0WU
MN-60NEfP[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTF7LkC1PVIh|ryPMkGxV2FPT0WU
EPLC-272HNIPoRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFS1dWlKSzVyPUG5MlM4ODhizszNMV3TRW5ITVJ?
SW948MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jSTWlEPTB;MUmuN|k{PCEQvF2=MV\TRW5ITVJ?
MOLT-13NX23NZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPpWYFKSzVyPUG5MlQ2PDZizszNMUHTRW5ITVJ?
HL-60NUHBUYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJyLkKxOFEh|ryPNIn5TnBUSU6JRWK=
CP50-MEL-BMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPYZ2o6UUN3ME2yNE41PzR6IN88US=>MmrkV2FPT0WU
NTERA-S-cl-D1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHzTWM2OD1{MD60PVc5KM7:TR?=NHz4OY5USU6JRWK=
KINGS-1NGn1b|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{izSmlEPTB;MkCuO|k3PyEQvF2=MleyV2FPT0WU
DOHH-2NWLEUYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTJyLkmwOkDPxE1?MXHTRW5ITVJ?
BB65-RCCNX7ncW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF65S2pKSzVyPUKwMlkzQDVizszNM{TzUnNCVkeHUh?=
NB12MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTCU2FmUUN3ME2yNU4xOzl2IN88US=>NX3uVYhJW0GQR1XS
KY821NFm5RmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3H3d2lEPTB;MkGuOVgzKM7:TR?=M4DHPHNCVkeHUh?=
PSN1NXuwbFlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\0OlZKSzVyPUKxMlY1PTNizszNMl3OV2FPT0WU
EGI-1NGHDVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJzLke0OVQh|ryPM4nLTXNCVkeHUh?=
CTV-1NIPPUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Tq[WlEPTB;MkKuN|A{OSEQvF2=MUDTRW5ITVJ?
TI-73NILweVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInjTo5KSzVyPUKyMlM1QThizszNNUHBVW8{W0GQR1XS
LCLC-103HM3HjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTJ{LkS3OVIh|ryPNVXlbpNzW0GQR1XS
D-542MGNWizeZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJ{LkW1OVgh|ryPM2Xod3NCVkeHUh?=
ATN-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTJ{Lk[0N|kh|ryPNHHLdWJUSU6JRWK=
SK-MEL-1NGrLPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmP2TWM2OD1{Mj64N|Y5KM7:TR?=MUDTRW5ITVJ?
HDLM-2MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTJ|LkG0O|gh|ryPMnzoV2FPT0WU
UM-UC-3M{fycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fZ[2lEPTB;MkOuNVk1PCEQvF2=M1PB[nNCVkeHUh?=
NCI-H1573MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzWdY1KSzVyPUKzMlQ3QDFizszNNGnpU5VUSU6JRWK=
NCI-H520NGnqXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHkW4tKSzVyPUKzMlQ6PDhizszNNX\X[GNKW0GQR1XS
ESS-1Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;QUGlEPTB;MkOuPFA2QSEQvF2=Moq2V2FPT0WU
COR-L88NEXjT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXjZnJRUUN3ME2yN{46PDd3IN88US=>Mk\GV2FPT0WU
TGBC24TKBNIrtOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJ2LkCzNVIh|ryPNU[1fGN[W0GQR1XS
HCC1937M{i4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF72UG1KSzVyPUK0MlEh|ryPNFnQZW9USU6JRWK=
RS4-11MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHSTWM2OD1{ND6xOFIh|ryPNITjdmRUSU6JRWK=
HCC38NWq0VmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXEdXVRUUN3ME2yOE4zOzl2IN88US=>NEfxdolUSU6JRWK=
RPMI-2650NHq4e3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTqfXFKSzVyPUK0MlYyPjJizszNNITLTZhUSU6JRWK=
P12-ICHIKAWAMkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDqeIdKSzVyPUK0MlYzPThizszNM3qxbXNCVkeHUh?=
YAPCNFX1UHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHKW25xUUN3ME2yOE45OjF2IN88US=>MlX3V2FPT0WU
NB13NVvEToVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvQTWM2OD1{NT6yOlEyKM7:TR?=MnLwV2FPT0WU
SK-N-ASNWnoVIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTJ3Lki1PFQh|ryPNW[1SJBUW0GQR1XS
SK-N-DZMmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXi3SHNsUUN3ME2yOk4xPDlizszNMYPTRW5ITVJ?
LS-411NM2jo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\veWlEPTB;Mk[uNlA{QCEQvF2=Ml3MV2FPT0WU
NCI-H810NILCUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\jXng6UUN3ME2yOk4{OTF{IN88US=>MlfhV2FPT0WU
NCI-SNU-1MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTJ4LkW0OVQh|ryPMYDTRW5ITVJ?
HHNF7nWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWL4fGZHUUN3ME2yOk42PTJ7IN88US=>NXPMUIR3W0GQR1XS
U-2-OSMn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DxOWlEPTB;Mk[uO|M5OiEQvF2=NVLvXotEW0GQR1XS
SF539MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPJV2RlUUN3ME2yOk45ODF6IN88US=>Mon1V2FPT0WU
NCI-H2052NGDSTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;QbZRKSzVyPUK3MlA5PiEQvF2=NI[zPYlUSU6JRWK=
A673NHnqbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2i1Z2lEPTB;MkeuNlExOiEQvF2=NYD4elJQW0GQR1XS
WM-115M121dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrtTWM2OD1{Nz63O|Y4KM7:TR?=M4LJ[3NCVkeHUh?=
SW48NIHyfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HaVmlEPTB;MkeuPFAxPSEQvF2=M1;renNCVkeHUh?=
NOMO-1MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jSZ2lEPTB;MkeuPFU{OiEQvF2=MWrTRW5ITVJ?
PC-3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJ5Lki5OFEh|ryPM3PmbHNCVkeHUh?=
UMC-11MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTJ5LkmzOFMh|ryPMkS3V2FPT0WU
U-118-MGNGnJVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XYdGlEPTB;MkiuNFEzOyEQvF2=MWfTRW5ITVJ?
NCI-H2452NIDLWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnOU|BKSzVyPUK4MlA5OjJizszNMVfTRW5ITVJ?
CAMA-1NHvDPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TQ[GlEPTB;MkiuPFU3PCEQvF2=NFn4N5BUSU6JRWK=
MC-IXCMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX63eGpnUUN3ME2yPU4zOzZ4IN88US=>MnPFV2FPT0WU
ES4MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XmO2lEPTB;MkmuN|E4OiEQvF2=MlzLV2FPT0WU
BHT-101M{S2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFv4clVKSzVyPUK5MlMzOSEQvF2=NH7CWmhUSU6JRWK=
KP-4NXvwPVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUj1SlNKUUN3ME2yPU42OTZizszNMoCxV2FPT0WU
CAL-54NWLucVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfoTWM2OD1{OT61OFQ2KM7:TR?=MX\TRW5ITVJ?
5637M4PaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7YSYpKSzVyPUK5MlY1OjFizszNM{DBfnNCVkeHUh?=
MOLT-16NIPWbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M36xTmlEPTB;MkmuO|I3QSEQvF2=M2fvVHNCVkeHUh?=
Ca-SkiMknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33mT2lEPTB;MkmuPVQ3KM7:TR?=M{Xa[nNCVkeHUh?=
AsPC-1NITYV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rNcGlEPTB;M{CuNFIyOiEQvF2=M4TGdHNCVkeHUh?=
MSTO-211HMlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfSRVRKSzVyPUOwMlE2KM7:TR?=MVvTRW5ITVJ?
L-428M1TjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTQS4NHUUN3ME2zNE41ODVizszNNHT0b|lUSU6JRWK=
SW1463M37kNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLrZYhKSzVyPUOwMlU{QDNizszNMlLLV2FPT0WU
NCI-H1648Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnqzTWM2OD1|MD61OVc1KM7:TR?=MWHTRW5ITVJ?
CAKI-1M1rWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DrcmlEPTB;M{CuO|cxOiEQvF2=NIHSZ2JUSU6JRWK=
YKG-1NEXoeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[5O3ZKSzVyPUOxMlAzPjNizszNNFH3S4ZUSU6JRWK=
A2058M2TJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\WSmlEPTB;M{GuNVE3PCEQvF2=NFv0TnFUSU6JRWK=
A375MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXK1OWpIUUN3ME2zNU4yPjl4IN88US=>Mle3V2FPT0WU
SNB75MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzvdWtQUUN3ME2zNU4zPDN3IN88US=>MlKyV2FPT0WU
SK-HEP-1MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13WSWlEPTB;M{GuOFI4OSEQvF2=NHrRSlZUSU6JRWK=
ME-180NXq3fJlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3EflZTUUN3ME2zNU43PTR{IN88US=>M2fjUHNCVkeHUh?=
NCI-H209NHvje4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvJN5lKSzVyPUOxMlgzPDdizszNNYS5fm4{W0GQR1XS
HC-1MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPv[WRKSzVyPUOyMlE1PDZizszNMXfTRW5ITVJ?
LB373-MEL-DNEn3OoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTN{LkG5O|Eh|ryPNIrIUpdUSU6JRWK=
SNU-387NFPzPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonHTWM2OD1|Mj6zNVkyKM7:TR?=NVnBWGF[W0GQR1XS
C32NUHFdG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fRcWlEPTB;M{KuN|M2OyEQvF2=NYf2XXN{W0GQR1XS
EW-13NFzlfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXoTWM2OD1|Mj65OFA5KM7:TR?=NXu5VZRyW0GQR1XS
BFTC-905MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLaTWM2OD1|Mz61NVM3KM7:TR?=MW\TRW5ITVJ?
NCI-H1299NH\FZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHi5UVBKSzVyPUOzMlU3OjFizszNNHLFbpJUSU6JRWK=
LU-135MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33COmlEPTB;M{OuPFAyKM7:TR?=NGCzWlJUSU6JRWK=
NCI-H2122NGjoR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDxTWM2OD1|Mz65PVY3KM7:TR?=Ml[xV2FPT0WU
SK-LMS-1NYjPRm96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTN2LkSxNFch|ryPNFj5WYlUSU6JRWK=
LNCaP-Clone-FGCM4XOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zNd2lEPTB;M{SuPFUyPSEQvF2=M4f6U3NCVkeHUh?=
NCI-H1092MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWr3fWw3UUN3ME2zOU4zPzR5IN88US=>NI\sS2NUSU6JRWK=
MS-1NFTpclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTN3LkOwN|gh|ryPMl;CV2FPT0WU
KYSE-510NW\EbGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nqUGlEPTB;M{WuOVA1OiEQvF2=MoTlV2FPT0WU
NCI-H1793NEL2PYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf6TWM2OD1|NT62OVQ2KM7:TR?=M{C0OXNCVkeHUh?=
MIA-PaCa-2MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkn6TWM2OD1|Nj6wOFk3KM7:TR?=M{noPXNCVkeHUh?=
EW-22NWLtUJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M171e2lEPTB;M{[uOFA4OiEQvF2=NX\1NJBMW0GQR1XS
IGR-1M4TFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTBTWM2OD1|Nj64NVg1KM7:TR?=MlLaV2FPT0WU
HT-1080NETOdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnJfHRiUUN3ME2zO{4yOjVizszNM4jvN3NCVkeHUh?=
M14NHqzdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTN5LkG2OFIh|ryPNYKzUWdRW0GQR1XS
786-0NEHuTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PwU2lEPTB;M{euNlc6PCEQvF2=NUfhOnoxW0GQR1XS
MZ2-MELNVPzPJptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkG2TWM2OD1|Nz60OVAyKM7:TR?=NID4[4tUSU6JRWK=
NCI-H510AM3O2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlz3TWM2OD1|Nz65OFEzKM7:TR?=NUTycnhMW0GQR1XS
LAN-6MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTN5Lkm1PFIh|ryPMUnTRW5ITVJ?
SW620MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvKTWM2OD1|OD60PVc1KM7:TR?=NETVN|JUSU6JRWK=
LB2241-RCCMl\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{e5RmlEPTB;M{muPFIxPSEQvF2=NHHaeVhUSU6JRWK=
Detroit562MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTRyLkGyOlgh|ryPMlHrV2FPT0WU
HNNW\Id5JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTRyLkG3PFIh|ryPMVHTRW5ITVJ?
HCT-15NYS0bVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXUblNYUUN3ME20NE42QTB5IN88US=>NUjOZ5VTW0GQR1XS
C2BBe1NXzIc5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPoUmNvUUN3ME20NE46OTV5IN88US=>MmHsV2FPT0WU
A498NFexbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\iUVJKSzVyPUSxMlMxOTVizszNM1[wRXNCVkeHUh?=
SK-MEL-24NXHu[29lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTRzLkS3NlUh|ryPNUjWdXliW0GQR1XS
OVCAR-5M{DNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTRzLke3Olch|ryPM2nWO3NCVkeHUh?=
NCI-H1792NULncottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PaR2lEPTB;NEGuPVgzOSEQvF2=NYGy[2hDW0GQR1XS
KOSC-2M3vmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPFS2lmUUN3ME20Nk4zPjl7IN88US=>MlPXV2FPT0WU
Mo-TNUDqbZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFT2XXBKSzVyPUSyMlg6PThizszNNGPoV4dUSU6JRWK=
CFPAC-1NHTD[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TpO2lEPTB;NEOuOFk1PCEQvF2=MVHTRW5ITVJ?
CAL-51NVTYVYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{Hxb2lEPTB;NEOuOVYxPSEQvF2=NXLGfYs4W0GQR1XS
RH-18NVHvNlZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTR|LkiwOUDPxE1?MnftV2FPT0WU
EC-GI-10NFLyZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYixcHlZUUN3ME20N{45OzR5IN88US=>NFTrSZdUSU6JRWK=
HSC-2MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFX6[GJKSzVyPUS0MlAxQSEQvF2=MUPTRW5ITVJ?
ML-2MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XhRWlEPTB;NEWuNlYzOSEQvF2=NEjHSHBUSU6JRWK=
KNS-81-FDNWG3XWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Xnd2lEPTB;NEWuO|M3PSEQvF2=NFfNTpVUSU6JRWK=
NB6M3vobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zjSmlEPTB;NE[uNVEyKM7:TR?=NXLrcVI4W0GQR1XS
MCF7MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qyUGlEPTB;NE[uOVU{OyEQvF2=M4H2[XNCVkeHUh?=
P30-OHKM1n6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTR4LkixNVch|ryPM1jX[XNCVkeHUh?=
BPH-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTR4Lkm4NFUh|ryPMkD4V2FPT0WU
U251NXmwd5IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3sSlVKSzVyPUS2Mlk6PCEQvF2=NHHMbJVUSU6JRWK=
MKN1NHHOUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTPTWM2OD12Nz61NVM4KM7:TR?=MXLTRW5ITVJ?
A431MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrNWVJDUUN3ME20O{45OzN6IN88US=>MlnCV2FPT0WU
C8166MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PERWlEPTB;NEmuNlA{QSEQvF2=NIDzVVdUSU6JRWK=
HELNHvsT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLP[WRSUUN3ME20PU41ODZ2IN88US=>MWfTRW5ITVJ?
RMG-INW\2XVA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\aWWxKSzVyPUS5MlQ1PDRizszNMYPTRW5ITVJ?
CAL-72M1\qbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrkVmZCUUN3ME20PU43ODd3IN88US=>NXzWb2ltW0GQR1XS
SW962NYLxWXNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLiUHAzUUN3ME20PU46OzN{IN88US=>MY\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).

Protocol(Only for Reference)

Kinase Assay:

[1]

Cellular receptor kinase phosphorylation assay Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.

Cell Assay:

[2]

Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
Concentrations 1 nM - 10 μM
Incubation Time 72 hours
Method

Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.

Animal Study:

[3]

Animal Models BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
Formulation 0.5% carboxymethylcellulose (CMC)
Dosages 10, 30 or 100 mg/kg
Administration Oral daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

[2] Rossler, J. et al., Int J Cancer, 2011, 128(11), 2748-2758.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02762513 Not yet recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center May 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3
NCT02636725 Recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University  ...more Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2

view more

Chemical Information

Download Axitinib SDF
Molecular Weight (MW) 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AG 013736
Solubility (25°C) * In vitro DMSO 35 mg/mL warming (90.56 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Customer Product Validation(4)


Click to enlarge
Rating
Source J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck
Method Spheroid Staining & Sectioning
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time 72 h
Results These results demonstrate that both U0126 and axitinib penetrated into the spheroid, resulting in downregulation of vimentin throughout the whole spheroid by more than 80% as compared to untreated spheroids.

Click to enlarge
Rating
Source J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck
Method Western Blot
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results Based on these data, there appears to be a threshold of 50% downregulation of VimPro-Fluc activity that must be reached before protein downregulation occurs.

Click to enlarge
Rating
Source J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck
Method Secondary assay
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results U0126, pF2341066, axitinib, and pKC412 caused significant inhibition of the invasive potential of Mda-Mb-231 spheroids. Conversely, dasatinib, a potent inhibitor of vimentin gene expression, did not significantly alter the invasive potential of MDA-MB-231 spheroids.

Click to enlarge
Rating
Source Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck
Method Western blot
Cell Lines HUVEC cells
Concentrations 0.1-10 nM
Incubation Time
Results Axitinib treatment blocks VEGFR2 phosphorylation.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Axitinib | Axitinib ic50 | Axitinib price | Axitinib cost | Axitinib solubility dmso | Axitinib purchase | Axitinib manufacturer | Axitinib research buy | Axitinib order | Axitinib mouse | Axitinib chemical structure | Axitinib mw | Axitinib molecular weight | Axitinib datasheet | Axitinib supplier | Axitinib in vitro | Axitinib cell line | Axitinib concentration | Axitinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us